RINVOQ is a JAK inhibitor for adults with active psoriatic arthritis in whom TNF blockers did not work well.

If you’re still experiencing PsA symptoms
after a TNF blocker like HUMIRA® or ENBREL® ,

RINVOQ is

Different

and may help

If you’re still experiencing PsA symptoms after a TNF blocker like HUMIRA® or ENBREL® ,

RINVOQ is

Different

and may help

Tackle psoriatic arthritis symptoms with RINVOQ

Proven in clinical studies, RINVOQ helps:

Illustration of joint pain at the knee Illustration of joint pain at the knee Illustration of joint pain at the knee

Significantly relieve joint pain, swelling and stiffness for the majority of people in 3 months—for some, PsA symptoms improved in just 2 weeks

Illustration of a psoriatic arthritis skin plaque Illustration of a psoriatic arthritis skin plaque Illustration of a psoriatic arthritis skin plaque

Leave skin* clear or almost clear for people with skin plaques

*RINVOQ is not approved to treat plaque psoriasis.

Illustration of painful joint damage Illustration of painful joint damage Illustration of painful joint damage

Stop further irreversible joint damage

Illustration of a battery low on power Illustration of a battery low on power Illustration of a battery low on power

Significantly reduce PsA fatigue


RINVOQ is a once-daily pill, not an injection.

A picture of the RINVOQ pill, which is a purple tablet with “a15” imprinted on it

Not actual size

Quick Poll

Have you ever been prescribed a TNF blocker for psoriatic arthritis (PsA)?

If you’re still experiencing PsA symptoms after a TNF blocker like HUMIRA® or ENBREL®, RINVOQ, a JAK inhibitor, is different and may help. See RINVOQ Results >

 

A rheumatologist is your best partner to finding a treatment plan that can help you reach your goals. Partner With a Rheumatologist >

 

Play an active part in your PsA treatment plan—staying engaged can help you manage PsA symptoms and reach your treatment goals. Partner With a Rheumatologist >

 

A rheumatologist can evaluate your PsA symptoms and help create a treatment plan that meets your unique needs. Find a Rheumatologist >

 

HUMIRA® and ENBREL® are examples of TNF blockers.  ENBREL® (etanercept) is a registered trademark of Immunex Corporation in the US.

Illustration of an “i" in a circle Illustration of an “i" in a circle Illustration of an “i" in a circle

Understanding the possible side effects of RINVOQ

Consider the benefits and risks of taking RINVOQ to make an informed treatment choice with your rheumatologist.

Learn more about side effects
Dollar sign icon Dollar sign icon Dollar sign icon

>95% of patients with insurance are covered for RINVOQ

>95% of patients with self- or employer-provided insurance plans or Medicare Part D are covered for RINVOQ.

The RINVOQ Complete Savings Card may help eligible commercially insured patients pay as little as $5 a month for RINVOQ.

See how you can save
Take the lead Take the lead Take the lead
Illustration of an email being sent Illustration of an email being sent Illustration of an email being sent

Stay in the know

Sign up for the latest tips, tools, and information to help you take PsA head on.

Become a RINVOQ Insider
Illustration of a book with two quotations Illustration of a book with two quotations Illustration of a book with two quotations

Share your RINVOQ story

Share your experience with RINVOQ to help inform and inspire others. To participate, please email us at info@SPEAKnetwork.net or call 877-861-6180.

Knowledge is power

Email or download the brochure to learn more about RINVOQ.

Please choose one

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ENBREL® (etanercept) is a registered trademark of Immunex Corporation in the US.

RINVOQ digital brochure

National commercial and Medicare Part D formulary coverage as of February 2023. <Percentage reflects anticipated coverage.>

Eligibility: Available to patients with commercial insurance coverage for RINVOQ® (upadacitinib) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit RINVOQSavingsCard.com or call 1.800.2RINVOQ for additional information. To learn about AbbVie’s privacy practices and your privacy choices, visit https://privacy.abbvie